Myriad Genetics, Inc. Financials

Market Capitalization $516.2 Million as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE	-3.97
Forward PE	37.33
Price to Sales TTM	$0.62
Price to Book MRQ	$0.73
Enterprise to Revenue	0.67
Enterprise to EBITDA	-19.02

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-12.20%
Operating Margin	-14.80%
Return on Assets TTM	-5.26%
Return on Equity TTM	-13.84%

Income Statement

Revenue TTM	$831,299,968
Revenue per Share TTM	$9.14
Quarterly Revenue Growth	-3.10%
Gross Profit TTM	$582,000,000
EBITDA	$-29,200,000
Net Income to Common TTM	$-101,400,000
Diluted EPS TTM	$-1.12
Quarterly Earnings Growth YoY	-3.12%

Balance Sheet

Total Cash MRQ	$91,800,000
Total Cash per Share MRQ	$1.00
Total Debt MRQ	$
Total Debt to Equity MRQ	22.36
Current Ratio MRQ	1.90
Book Value per Share MRQ	$7.65

Cash Flow

Operating Cash Flow TTM	$-6,400,000
Levered Free Cash Flow TTM	$18,675,000

MYGN Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	91,300,000
Float Shares	89,780,771
Avg 10 Volume	1,381,525
Avg 30 Volume	None
Shares Short	8,383,042
Short Ratio	3.60
Short % of Shares	12.84%
% Held by Insiders	2.77%
% Held by Institutions	104.21%

Stock Price Summary

Beta	1.85
Fifty Two Week Low	$3.81
Fifty Two Week High	$29.30
Fifty Two Week Change	-351.07%
Day 50 MA	$5.28
Day 200 MA	$13.04

Dividends and Splits

Forward Annual Dividend Rate	$21.00
Forward Annual Dividend Yield	375.00%
Trailing Annual Dividend Rate	$3.50
Trailing Annual Dividend Yield	62.50%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2009-07-01
Last Split Factor
Last Split Date	2009-03-26